Database Analysis on the Relationships Between Nonsteroidal Anti-inflammatory Drug Treatment Variables and Incidence of Acute Myocardial Infarction in Japanese Patients with Osteoarthritis and Chronic Low Back Pain.


Journal

Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864

Informations de publication

Date de publication:
03 2021
Historique:
received: 04 11 2020
accepted: 15 01 2021
pubmed: 6 2 2021
medline: 15 4 2021
entrez: 5 2 2021
Statut: ppublish

Résumé

We aimed to analyze the relationships between nonsteroidal anti-inflammatory drug (NSAID) treatment variables and the incidence of acute myocardial infarction (AMI) in Japanese patients with osteoarthritis (OA) and chronic low back pain (CLBP) using the data from a large-scale, real-world database. We retrospectively analyzed anonymized claims data from the Japanese Medical Data Center of medical insurance beneficiaries who were prescribed NSAIDs for OA and/or CLBP from 2009 to 2018. Of 180,371 patients, 89.3% received NSAIDs as first-line analgesics (oral, 90.3%; patch, 80.4%; other transdermal drugs, 24.0%). Incidence of AMI was 10.27 per 10,000 person-years (95% confidence interval 9.20-11.34) in the entire study population. There was a trend towards increased risk in patients using NSAIDs for more than 5 years (P = 0.0784) than in those using NSAIDs for less than 1 year. Risk of AMI significantly increased with age and comorbidities of diabetes and cardiovascular disease (CVD). The risk for AMI was similar for patients who consistently used NSAIDs compared to those using them intermittently and patients who used patch compared to oral NSAIDs. Elderly patients used NSAIDs more consistently and used NSAID patches more frequently. In Japanese patients with OA and CLBP, we saw a trend of increased risk for AMI in patients using NSAIDs for more than 5 years. Elderly patients had a higher prevalence of diabetes, hypertension, and other CVD which increased the risk of AMI. Although NSAID patches were preferred to oral NSAIDs in elderly patients, risk for AMI was similar between the two modalities. Therefore, we suggest using NSAIDs carefully, especially in elderly patients and those at risk of developing CVD.

Identifiants

pubmed: 33544304
doi: 10.1007/s12325-021-01629-6
pii: 10.1007/s12325-021-01629-6
pmc: PMC7932944
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0
Pharmaceutical Preparations 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

1601-1613

Références

Briggs AM, Woolf AD, Dreinhöfer K, et al. Reducing the global burden of musculoskeletal conditions. Bull World Health Organ. 2018;96(5):366.
pubmed: 29875522 pmcid: 5985424 doi: 10.2471/BLT.17.204891
Tsang A, Von Korff M, Lee S, et al. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain. 2008;9(10):883–91.
pubmed: 18602869 doi: 10.1016/j.jpain.2008.05.005 pmcid: 18602869
International Association for the Study of Pain. Musculoskeletal pain fact sheets. https://www.iasp-pain.org/Advocacy/Content.aspx?ItemNumber=1101 . Assessed 01 Dec 2020.
WHO. Musculoskeletal conditions. https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions . Assessed 02 Nov 2020.
Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–96.
pubmed: 23245607 pmcid: 6350784 doi: 10.1016/S0140-6736(12)61729-2
Urits I, Burshtein A, Sharma M, et al. Low back pain, a comprehensive review: pathophysiology, diagnosis, and treatment. Curr Pain Headache Rep. 2019;23(3):23.
pubmed: 30854609 doi: 10.1007/s11916-019-0757-1 pmcid: 30854609
Nijs J, Apeldoorn A, Hallegraeff H, et al. Low back pain: guidelines for the clinical classification of predominant neuropathic, nociceptive, or central sensitization pain. Pain Phys. 2015;18(3):E333–46.
doi: 10.36076/ppj.2015/18/E333
Yoshimura N. Epidemiology of osteoarthritis in Japan: the ROAD study. Clin Calcium. 2011;21(6):821–5.
pubmed: 21628795 pmcid: 21628795
Iizuka Y, Iizuka H, Mieda T, et al. Prevalence of chronic nonspecific low back pain and its associated factors among middle-aged and elderly people: an analysis based on data from a musculoskeletal examination in Japan. Asian Spine J. 2017;11(6):989.
pubmed: 29279756 pmcid: 5738322 doi: 10.4184/asj.2017.11.6.989
Blyth FM, Briggs AM, Schneider CH, Hoy DG, March LM. The global burden of musculoskeletal pain—where to from here? Am J Public Health. 2019;109(1):35–40.
pubmed: 30495997 pmcid: 6301413 doi: 10.2105/AJPH.2018.304747
Kojima G, Iliffe S, Taniguchi Y, Shimada H, Rakugi H, Walters K. Prevalence of frailty in Japan: a systematic review and meta-analysis. J Epidemiol. 2017;27(8):347–53.
pubmed: 28142044 doi: 10.1016/j.je.2016.09.008 pmcid: 28142044
Ebata-Kogure N, Murakami A, Nozawa K, et al. Treatment and healthcare cost among patients with hip or knee osteoarthritis: a cross-sectional study using a real-world claims database in Japan between 2013 and 2019. Clin Drug Investig. 2020;40(11):1071–84.
pubmed: 32965598 doi: 10.1007/s40261-020-00968-6 pmcid: 32965598
The Japanese Orthopaedic Association. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines adapted to Japanese by Japanese Orthopaedic Association (JOA) Committee on clinical practice guideline on the management of osteoarthritis of the knee. Osteoarthritis Research Society International 2012.
Japanese Orthopaedic Association. Clinical practice guideline on the management of osteoarthritis of the hip. 2nd ed. Tokyo: Nankodo; 2016.
Gore M, Tai KS, Sadosky A, Leslie D, Stacey BR. Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community-based settings. Pain Pract. 2012;12(7):550–60.
pubmed: 22304678 doi: 10.1111/j.1533-2500.2012.00532.x pmcid: 22304678
Akazawa M, Mimura W, Togo K, et al. Patterns of drug treatment in patients with osteoarthritis and chronic low back pain in Japan: a retrospective database study. J Pain Res. 2019;12:1631.
pubmed: 31190973 pmcid: 6535438 doi: 10.2147/JPR.S203553
Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based. Expert Consens Guidel Osteoarthr Cartil. 2008;16(2):137–62.
doi: 10.1016/j.joca.2007.12.013
Bannuru RR, Osani M, Vaysbrot E, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartil. 2019;27(11):1578–89.
doi: 10.1016/j.joca.2019.06.011
Association TJO. Clinical practice guideline on the management of low back pain. 2nd ed. Tokyo: Nankodo; 2019.
Schmidt M, Lamberts M, Olsen A-MS, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J. 2016;37(13):1015–23.
pubmed: 26984863 doi: 10.1093/eurheartj/ehv505 pmcid: 26984863
Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. BMJ. 2017;357:j1909.
pubmed: 28487435 pmcid: 5423546 doi: 10.1136/bmj.j1909
Ungprasert P, Srivali N, Thongprayoon C. Nonsteroidal anti-inflammatory drugs and risk of incident heart failure: a systematic review and meta-analysis of observational studies. Clin Cardiol. 2016;39(2):111–8.
pubmed: 26720629 doi: 10.1002/clc.22502 pmcid: 26720629
Ungprasert P, Matteson EL, Thongprayoon C. Nonaspirin nonsteroidal anti-inflammatory drugs and risk of hemorrhagic stroke: a systematic review and meta-analysis of observational studies. Stroke. 2016;47(2):356–64.
pubmed: 26670086 doi: 10.1161/STROKEAHA.115.011678 pmcid: 26670086
Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302–8.
pubmed: 16740558 pmcid: 1473048 doi: 10.1136/bmj.332.7553.1302
Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
pubmed: 21224324 pmcid: 3019238 doi: 10.1136/bmj.c7086
Wang H, Bai J, He B, Hu X, Liu D. Osteoarthritis and the risk of cardiovascular disease: a meta-analysis of observational studies. Sci Rep. 2016;6:39672.
pubmed: 28004796 pmcid: 5177921 doi: 10.1038/srep39672
Atiquzzaman M, Karim ME, Kopec J, Wong H, Anis AH. Role of nonsteroidal antiinflammatory drugs in the association between osteoarthritis and cardiovascular diseases: a longitudinal study. Arthritis Rheumatol. 2019;71(11):1835–43.
pubmed: 31389178 doi: 10.1002/art.41027 pmcid: 31389178
Wang H-C, Su Y-C, Luk H-N, Wang J-H, Hsu C-Y, Lin S-Z. Increased risk of strokes in patients with chronic low back pain (CLBP): a nationwide population-based cohort study. Clin Neurol Neurosurg. 2020;192:105725.
pubmed: 32086183 doi: 10.1016/j.clineuro.2020.105725 pmcid: 32086183
Hirayama A, Tanahashi N, Daida H, et al. Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis. Circ J. 2014;78(1):194–205.
pubmed: 24152722 doi: 10.1253/circj.CJ-12-1573 pmcid: 24152722
Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013;22(6):559–70.
pubmed: 23616423 pmcid: 3749466 doi: 10.1002/pds.3437
Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. Z Evid Fortbild Qual Gesundhwes. 2016;115:33–48.
pubmed: 27837958 doi: 10.1016/j.zefq.2016.07.010 pmcid: 27837958
Ministry of Education, Culture, Sports, Science and Technology Japan and Ministry of Health, Labour and Welfare. Ethical guidelines for medical and health research involving human subjects. 2018. https://www.lifescience.mext.go.jp/files/pdf/n2181_01.pdf . Assessed 10 Dec 2020.
Patel TN, Goldberg KC. Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med. 2004;164(8):852–6.
pubmed: 15111370 doi: 10.1001/archinte.164.8.852 pmcid: 15111370
Bhala N, Emberson J, Merhi A, et al. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–79.
pubmed: 23726390 doi: 10.1016/S0140-6736(13)60900-9 pmcid: 23726390
Bruyère O, Cooper C, Pelletier J-P, Maheu E, Rannou F, Branco J, et al., editors. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis—from evidence-based medicine to the real-life setting. Semin Arthritis Rheum 2016;45:S3-S11.
Olsen A-MS, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015;313(8):805–14.
doi: 10.1001/jama.2015.0809
Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169(2):141–9.
pubmed: 19171810 doi: 10.1001/archinternmed.2008.525 pmcid: 19171810
Kohli P, Steg PG, Cannon CP, et al. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. Am J Med. 2014;127(1):53–60.
pubmed: 24280110 doi: 10.1016/j.amjmed.2013.08.017 pmcid: 24280110
Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009;2(3):155–63.
pubmed: 20031832 doi: 10.1161/CIRCOUTCOMES.108.805689 pmcid: 20031832
Schjerning Olsen A-M, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226–35.
doi: 10.1161/CIRCULATIONAHA.110.004671
McCarberg BH. NSAIDs in the older patient: balancing benefits and harms. Pain Med. 2013;14(suppl_1):S43–4.
pubmed: 24373111 doi: 10.1111/pme.12253 pmcid: 24373111
Rodgers JL, Jones J, Bolleddu SI, et al. Cardiovascular risks associated with gender and aging. J Cardiovasc Dev Dis. 2019;6(2):19.
pmcid: 6616540 doi: 10.3390/jcdd6020019
Garoufalis S, Kouvaras G, Vitsias G, et al. Comparison of angiographic findings, risk factors, and long term follow-up between young and old patients with a history of myocardial infarction. Int J Cardiol. 1998;67(1):75–80.
pubmed: 9880203 doi: 10.1016/S0167-5273(98)00194-6 pmcid: 9880203
Dagenais S, Garbedian S, Wai EK. Systematic review of the prevalence of radiographic primary hip osteoarthritis. Clin Orthop Relat Res. 2009;467(3):623.
pubmed: 19037710 doi: 10.1007/s11999-008-0625-5 pmcid: 19037710
Loeser RF. Aging and osteoarthritis. Curr Opin Rheumatol. 2011;23(5):492.
pubmed: 21709557 pmcid: 3377970 doi: 10.1097/BOR.0b013e3283494005
Meucci RD, Fassa AG, Faria NMX. Prevalence of chronic low back pain: systematic review. Rev Saude Publica. 2015;49:73.
doi: 10.1590/S0034-8910.2015049005874
Gidding SS, Sood E. Preventing cardiovascular disease: going beyond conventional risk assessment. Circulation. 2015;131(3):230–1.
pubmed: 25583138 doi: 10.1161/CIRCULATIONAHA.114.013886 pmcid: 25583138

Auteurs

Shogo Kikuchi (S)

Department of Public Health, Aichi Medical University School of Medicine, Aichi, Japan.

Kanae Togo (K)

Pfizer Japan Inc., Tokyo, Japan. kanae.togo@pfizer.com.

Nozomi Ebata (N)

Pfizer Japan Inc., Tokyo, Japan.

Koichi Fujii (K)

Pfizer Japan Inc., Tokyo, Japan.

Naohiro Yonemoto (N)

Pfizer Japan Inc., Tokyo, Japan.

Lucy Abraham (L)

Pfizer Ltd., Surrey, UK.

Takayuki Katsuno (T)

Department of Nephrology and Rheumatology, Aichi Medical University, Aichi, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH